Palatin Technologies Inc $PTN

What the company doesAI summary of filing

Palatin Technologies is a clinical-stage biopharmaceutical company developing medicines that modulate the melanocortin receptor system. The company's primary focus is developing MC4R selective agonists for obesity treatment, particularly in rare neuroendocrine diseases such as hypothalamic obesity, Prader-Willi syndrome, and Bardet-Biedl syndrome, with a long-acting peptide candidate planned for Phase 1 in the first half of 2027 and an oral small molecule candidate planned for Phase 1 in the second half of 2027. Palatin is also developing MC1R agonist products for inflammatory and autoimmune diseases, including the oral formulation PL8177 for ulcerative colitis, which reported positive Phase 2 results in early 2025. The company generates revenue through upfront payments, milestone payments, and royalties from licensing collaborations, including recent agreements with Boehringer Ingelheim for retinal disease compounds and Altanispac Labs for the dry eye disease candidate PL9643; the company has a history of operating losses and substantial doubt regarding its ability to continue as a going concern. [10-K 2026-09-28]

Segments: MC4R agonists for obesity and rare metabolic disorders, MC1R agonists for inflammatory and autoimmune diseases, PL9643 for dry eye disease (sublicensed to Altanispac), Retinal disease compounds (licensed to Boehringer Ingelheim)